2.7.5 参考文献 2.7.5 参考文献 [1] Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842-7. [2] Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48(6):829-35. [3] Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44. [4] Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49(2):206-12. [5] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6. [6] Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38(6):727-35. [7] Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26(11):1346-53. [8] 照井正，田上八朗．汎発性膿疱性乾癬治療ガイドライン 2002;臨皮 57(5 増):125-30． [9] Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83. [10] Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20(3):557-60. [11] Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43(7):1478-87. [12] Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50(3):699-706. [13] Khilji F, A., Gonzales M, Finalay A, Y. Clinical meaning of change in dermatology life quality index scores.Br J Dermatol 2002;147(Suppl. 62):50. [14] Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114(3):587-90. [15] Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120(2):211-6. 334 2.7.5 参考文献 [16] Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140(2):237-42. [17] Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117(6):1531-7. [18] 日本呼吸器学会市中肺炎診療ガイドライン作成委員会．肺炎の重症度分類と入院，外来 治療の目安．日本呼吸器学会「呼吸器感染症に関するガイドライン」成人市中肺炎治療の基 本的考え方．東京:日本呼吸器学会 2002 p20-1． 335
© Copyright 2024 ExpyDoc
